The therapeutic potential of the proteasome in leukaemia

被引：15

作者：

McCloskey, Scott Marshall ^{[1
]}

McMullin, Mary Frances ^{[2
]}

Walker, Brian ^{[3
]}

Irvine, Alexandra E. ^{[1
]}

机构：

[1] Queens Univ Belfast, CCRCB, Belfast, Antrim, North Ireland

[2] Queens Univ Belfast, Dept Haematol, Belfast, Antrim, North Ireland

[3] Queens Univ Belfast, Sch Pharm, Belfast, Antrim, North Ireland

来源：

HEMATOLOGICAL ONCOLOGY | 2008年 / 26卷 / 02期

关键词：

leukaemia; bortezomib; proteasome;

D O I：

10.1002/hon.848

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Many cellular processes converge on the proteasome, and its key regulatory role is increasingly being recognized. Proteasome inhibition allows the manipulation of many cellular pathways including apoptotic and cell cycle mechanisms. The proteasome inhibitor bortezomib has enhanced responses in newly diagnosed patients with myeloma and provides a new line of therapy in relapsed and refractory patients. Malignant cells are more sensitive to proteasome inhibition than normal haematopoietic cells. Proteasome inhibition enhances many conventional therapies and its role in leukaemia is promising. Copyright (C) 2008 John Wiley & Sons, Ltd.

引用

收藏

页码：73 / 81

页数：9

相关论文

共 103 条

[1]

β-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system [J].

Almeida, CG ;

Takahashi, RH ;

Gouras, GK .

JOURNAL OF NEUROSCIENCE, 2006, 26 (16) :4277-4288

[2]

MYC degradation: deubiquitinating enzymes enter the dance [J].

Amati, Bruno ;

Lobo, Victor J. Sanchez-Arevalo .

NATURE CELL BIOLOGY, 2007, 9 (07) :729-731

[3]

Mechanism and function of deubiquitinating enzymes [J].

Amerik, AY ;

Hochstrasser, M .

BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1695 (1-3) :189-207

[4]

The proteasome [J].

Bochtler, M ;

Ditzel, L ;

Groll, M ;

Hartmann, C ;

Huber, R .

ANNUAL REVIEW OF BIOPHYSICS AND BIOMOLECULAR STRUCTURE, 1999, 28 :295-+

[5]

Phosphorylation of 20S proteasome alpha subunit C8 (α7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by γ-interferon [J].

Bose, S ;

Stratford, FLL ;

Broadfoot, KI ;

Mason, GGF ;

Rivett, AJ .

BIOCHEMICAL JOURNAL, 2004, 378 :177-184

[6]

Targeting NF-κB in hematologic malignancies [J].

Braun, T ;

Carvalho, G ;

Fabre, C ;

Grosjean, J ;

Fenaux, P ;

Kroemer, G .

CELL DEATH AND DIFFERENTIATION, 2006, 13 (05) :748-758

[7]

Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion [J].

Bulteau, AL ;

Lundberg, KC ;

Humphries, KM ;

Sadek, HA ;

Szweda, PA ;

Friguet, B ;

Szweda, LI .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (32) :30057-30063

[8]

Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the "immunoproteasome" [J].

Cardozo, C ;

Kohanski, RA .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (27) :16764-16770

[9]

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib [J].

Chauhan, D ;

Catley, L ;

Li, GL ;

Podar, K ;

Hideshima, T ;

Velankar, M ;

Mitsiades, C ;

Mitsiades, N ;

Yasui, H ;

Letai, A ;

Ovaa, H ;

Berkers, C ;

Nicholson, B ;

Chao, TH ;

Neuteboom, STC ;

Richardson, P ;

Palladino, MA ;

Anderson, KC .

CANCER CELL, 2005, 8 (05) :407-419

[10]

CHEN ZJ, 1990, J BIOL CHEM, V265, P21835

← 1 2 3 4 5 6 7 8 9 10 →